Fibulin‐2: A potential regulator of immune dysfunction after bone trauma
Immunity, Inflammation and Disease · 2023
DOI: 10.1002/iid3.846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Shidan Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing, People's R…. Hauptthemen laut MEDLINE: Calcium-Binding Proteins, Extracellular Matrix Proteins, Bone and Bones, Immune System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To reveal the relationship between the fibulin‐2 protein and immune dysfunction after bone trauma.
Methods
Individuals who were admitted to the study were divided into a bone trauma group, a recovered from bone trauma group and a volunteer without bone trauma group based on the reason for admission. Fibulin‐2 levels in the three groups were compared. Fibulin‐2 ‐knockout ( fibulin‐2 −/− ) mice and wild‐type (WT) mice were used to detect susceptibility to infection. Hematoxylin and eosin (HE) staining and immunohistochemical staining were employed to observe pathological changes in each organ from fibulin‐2 −/− mice and WT mice.
Results
In total, 132 patients were enrolled in this study. The fibulin‐2 level in the bone trauma group was lower than that in the recovered bone trauma group (3.39 ± 1.41 vs. 4.30 ± 1.38 ng/mL, t = 2.948, p < .05) and also lower than that in the volunteers without bone trauma group (3.39 ± 1.41 vs. 4.73 ± 1.67 ng/mL, t = 4.135, p < .05). Fibulin‐2 −/− mice are more prone to infection. Compared with those in WT mice, spleen function and thymus function in fibulin‐2 −/− mice were impaired. Immunohistochemical staining revealed that compared with those in WT mice, significantly fewer CD4+ T cells, CD8+ T cells, and CD19+ B cells were noted in the spleen and thymus of fibulin‐2 −/− mice.
Conclusions
The plasma fibulin‐2 level was lower in patients with bone trauma. Decreased fibulin‐2 is associated with immune dysfunction after bone trauma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
- Department of Orthopaedics, Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
- Department of Emergency, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
- Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
- Department of Military Traffic Injury Prevention, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
- Department of Stem Cell and Regenerative Medicine, State Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing, People's Republic of China.
ORCID-Profile: Shidan Li, Qiaohui Li
Zitieren
APA
Li, S., Jiang, H., Wang, S., Li, Y., Guo, D., Zhan, J., Li, Q., Meng, H., Chen, A., Chen, L., Dai, X., Li, X., Xing, W., Li, L., & Fei, J. (2023). Fibulin‐2: A potential regulator of immune dysfunction after bone trauma. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.846
Vancouver
Li S, Jiang H, Wang S, Li Y, Guo D, Zhan J, et al. Fibulin‐2: A potential regulator of immune dysfunction after bone trauma. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.846
BibTeX
@article{Li2023,
author = {Li, Shidan and Jiang, Hao and Wang, Shaochuan and Li, Youbin and Guo, Debin and Zhan, Jijie and Li, Qiaohui and Meng, Hao and Chen, Ankang and Chen, Limin and Dai, Xiaoyan and Li, Xiaoming and Xing, Wei and Li, Lei and Fei, Jun},
title = {Fibulin‐2: A potential regulator of immune dysfunction after bone trauma},
journal = {Immunity, Inflammation and Disease},
year = {2023},
doi = {10.1002/iid3.846}
}
EUVIMED